Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07487623 (RESQUETI) for Liver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTION is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
University of GuadalajaraEvaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). 26 Biomarker-Driven
Clinical Trial NCT07487623 (RESQUETI) is an interventional study for Liver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTION that is recruiting. It started on 11 October 2025 with plans to enroll 26 participants. Led by University of Guadalajara, it is expected to complete by 15 May 2026. The latest data from ClinicalTrials.gov was last updated on 23 March 2026.
Brief Summary
The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection.
The study will compare the investigational supplement with an active control (whey protein alone) to determine whether t...
Show MoreOfficial Title
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
Conditions
Liver Disease ChronicHEPATITIS C VIRUS CHRONIC INFECTIONPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- RESQUETI
- CEI 183/23
NCT ID Number
Start Date (Actual)
2025-10-11
Last Update Posted
2026-03-23
Completion Date (Estimated)
2026-05-15
Enrollment (Estimated)
26
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
liver disease chronic
hcv
resveratrol
quercetin
taurine
inulin
frailty
whey protein
hcv
resveratrol
quercetin
taurine
inulin
frailty
whey protein
Primary Purpose
Supportive Care
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Triple
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalSuplement powdered supplement containing resveratrol, quercetin, taurine, insulin, and whey protein. | resveratrol, quercetin, taurine, whey protein, and inulin powdered supplement containing resveratrol, quercetin, taurine, whey protein, and inulin |
Active ComparatorWhey protein Whey protein | whey protein powdered supplement containing whey protein |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Liver function measurements | Serum concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) | From enrollment to the end of treatment at 12 weeks |
Quality of life (CLDQ) | Quality of life was assessed using the Chronic Liver Disease Questionnaire (CLDQ), which evaluates domains such as fatigue, worry, systemic symptoms, abdominal symptoms, activity, and overall assessment. The maximum score is 7, indicating better quality of life. | From enrollment to the end of treatment at 12 weeks |
Frailty | Physical frailty assessed using the Liver Frailty Index (LFI) | The LFI includes grip strength, timed chair stands, and balance testing. Frailty classifications were determined using previously established LFI cutoffs: robust (LFI < 3.2), prefrail (LFI 3.2-4.4), and frail (LFI ≥ 4.5). |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Pro-inflammatory cytokines | Serum concentrations of pro-inflammatory cytokines (IL-1β, TNF-α, TGF-β) | From enrollment to the end of treatment at 12 weeks |
Antioxidant activity | Serum concentrations of antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) | From enrollment to the end of treatment at 12 weeks |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Patients with liver disease secondary to chronic hepatitis C virus infection who attend the outpatient Hepatitis Clinic of the Gastroenterology Department at Hospital Civil Fray Antonio Alcalde.
Child-Pugh score < 8 points. Age 18-69 years. Both sexes. Signed informed consent.
-
- Patients with alcohol consumption within the past 6 months. Patients with a history of acute-on-chronic liver failure (ACLF). Patients with persistent hepatic encephalopathy. Patients unable to perform frailty assessments. Patients with refractory ascites. Patients with a history of hepatorenal syndrome. Patients with a history of hepatopulmonary syndrome. Patients with chronic kidney disease. Patients with autoimmune diseases. Patients with any type of cancer. Patients with dementia or other significant mental illnesses. Use of protein supplements or probiotics.
University of Guadalajara15 active studies to explore- Hospital Civil de Guadalajara
- Centro Universitario de Ciencias de la Salud, Mexico
Study Central Contact
Contact: Juan Roberto Rodriguez-Echevarria, PhD, +52 33 18 23 13 10, [email protected]
2 Study Locations in 1 Countries
Jalisco
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, 44280, Mexico
José Antonio Velarde Ruiz, MD, Contact, +52 33 12 22 8507, [email protected]
Recruiting
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
Roberto, Doctor in Science, Contact
Recruiting